Broad-spectrum antibiotics are akin to nuclear bombs, obliterating each prokaryote they meet. They’re efficient at eliminating pathogens, positive, however they are not so nice for sustaining a wholesome microbiome. Ideally, we want precision antimicrobials that may goal solely the dangerous micro organism whereas ignoring the opposite species we want in our our bodies, leaving them to thrive. Enter SNIPR BIOME, a Danish firm based to do exactly that. Its first drug—SNIPR001—is presently in medical trials.
The drug is designed for folks with cancers involving blood cells. The chemotherapy these sufferers want may cause immunosuppression together with elevated intestinal permeability, to allow them to’t combat off any infections they could get from micro organism that escape from their guts into their bloodstream. The mortality price from such infections in these sufferers is round 15–20 p.c. Many of the infections are brought on by E. coli, and far of this E. coli is already immune to fluoroquinolones, the antibiotics generally used to deal with a lot of these infections.
The staff at SNIPR BIOME engineers bacteriophages, viruses that focus on micro organism, to make them hyper-selective. They began by screening 162 phages to seek out those who would infect a broad vary of E. coli strains taken from folks with bloodstream or urinary tract infections, in addition to from the center of wholesome folks. They settled on a set of eight completely different phages. They then engineered these phages to hold the genes that encode the CRISPR DNA-editing system, together with the RNAs wanted to focus on editing to a variety of important genes within the E. coli genome. This strategy has been proven to forestall the evolution of resistance.
After testing the flexibility of those eight engineered phages to kill the E. coli panel alone and together, they determined {that a} group of 4 of them was the simplest, naming the combination SNIPR001. But 4 engineered phages don’t make a drug; the staff confirmed that SNIPR001 stays steady for 5 months in storage and that it doesn’t have an effect on another intestine micro organism.
The researchers confirmed that SNIPR001 was well-tolerated in Göttingen minipigs—after oral administration, the pigs didn’t exhibit any medical, biochemical, hematological, or immunological results, and no phages had been discovered of their blood, so there was no systemic publicity. In mice, oral administration of SNIPR001 decreased the quantity of goal E. coli within the feces, and not one of the recovered E. coli had been immune to the phage cocktail.
Phage remedy, tempting although it’s in principle, has a checkered historical past at finest. But SNIPR BIOME’s purpose of utilizing CRISPR to exactly goal solely dangerous micro organism might revitalize this method, permitting us to proceed vanquishing our bacterial foes with out selling drug resistance.
Nature Biotechnology, 2023. DOI: 10.1038/s41587-023-01759-y